Patent litigation


A federal judge in the U.S. District Court for the District of New Jersey found that Pfizer Inc.'s patents for celecoxib, the active ingredient in Celebrex®, for formulations containing celecoxib and for methods of treatment using celecoxib are valid and enforceable, and are infringed by Teva Pharmaceuticals U.S.A., Inc. Teva sought to produce and market a generic version of Pfizer's blockbuster drug Celebrex® for the treatment of osteoarthritis and rheumatoid arthritis. The Court found that Teva failed to prove obviousness, inequitable conduct, a violation of the best mode requirement, or obvious-type double patenting by clear and convincing evidence. Thus, the patents-in-suit are neither invalid nor unenforceable, and Teva has infringed the patents.

Email Disclaimer